Results 21 to 30 of about 32,062 (289)

Achieving the unimaginable : Health equity in haemophilia [PDF]

, 2020
Historically, treatment based on the availability of clotting factor replacement has resulted in an arcane guideline for the correction of factor deficiencies in people with haemophilia (PwH).
Erik Berntorp, Dolan, Gerry,, O’Mahony, Brian, Pam Wilton, Skinner, Mark W.,, Wilton, Pam,, O’Mahony, Brian,, Diane Nugent, Wilton, Pam, Nugent, Diane,, Gerry Dolan, Dolan, Gerry, Nugent, Diane, Berntorp, Erik,, Skinner, Mark W., Berntorp, Erik, Jamie O’Hara, O’Hara, Jamie,, Lund University., Mark W. Skinner, O’Hara, Jamie, Brian O’Mahony   +21 more
core   +1 more source

Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo. [PDF]

PLoS ONE, 2017
Canine models of severe haemophilia resemble their human equivalents both regarding clinical bleeding phenotype and response to treatment. Therefore pre-clinical studies in haemophilia dogs have allowed researchers to make valuable translational ...
Daniel Elenius Madsen, Timothy C Nichols, Elizabeth P Merricks, Emily K Waters, Bo Wiinberg   +4 more
doaj   +1 more source

Haemophilia and joint disease: pathophysiology, evaluation and management [PDF]

, 2011
In patients with haemophilia, regular replacement therapy with clotting factor concentrates (prophylaxis) is effective in preventing recurrent bleeding episodes into joints and muscles.
Erik Berntorp, Knobe, Karin, Karin Knobe, Berntorp, Erik   +3 more
core   +1 more source

Three-Decade Successive Establishment of Care for Women/Girls from Families with Haemophilia

The Application of Clinical Genetics, 2022
Ampaiwan Chuansumrit,1 Werasak Sasanakul,1 Nongnuch Sirachainan,1 Suttikarn Santiwatana,1 Praguywan Kadegasem,1 Pakawan Wongwerawattanakoon,2 Noppawan Tungbubpha,1 Juthamard Chantaraamporn1 1Department of Pediatrics, Faculty of Medicine, Ramathibodi ...
Chuansumrit A, Sasanakul W, Sirachainan N, Santiwatana S, Kadegasem P, Wongwerawattanakoon P, Tungbubpha N, Chantaraamporn J   +7 more
doaj  

The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study

Orphanet Journal of Rare Diseases, 2022
Background Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families.
Simon Fletcher, Kathryn Jenner, Luke Pembroke, Michael Holland, Kate Khair   +4 more
doaj   +1 more source

Evaluation of platelet function in thrombocytopenia

Platelets, 2018
Whole blood aggregometry is a functional assay for determination of platelet function. Until now, whole blood aggregometry has not been considered feasible at low platelet counts.
Mette Tiedemann Skipper, Peter Rubak, Jesper Stentoft, Anne-Mette Hvas, Ole Halfdan Larsen   +4 more
doaj   +1 more source

Causes of death and mortality trends related to hemophilia in Brazil, 1999 to 2016

Hematology, Transfusion and Cell Therapy, 2021
Introduction: Multiple cause of death methodology enhances mortality studies beyond the traditional underlying cause of death approach. Aim: This study aims to describe causes of death and mortality issues related to haemophilia with the use of multiple ...
Augusto Hasiak Santo
doaj   +1 more source

Evolution of congenital haemophilia care in Taiwan

Journal of the Formosan Medical Association, 2022
Haemophilia care in Taiwan has come a long way over the past 35 years, from the absence of specialised haemophilia treatment centres before 1984 to the establishment of treatment centers in the majority of medical centers, the listing of haemophilia as a
Yeu-Chin Chen, Chia-Yau Chang, Shin-Nan Cheng, Ru-Yu Pan, Yu-Lueng Shih, Tsung-Ying Li, Sheng-Hao Wang   +6 more
doaj   +1 more source

Haemophilia A and haemophilia B: molecular insights [PDF]

Molecular Pathology, 2002
This review focuses on selected areas that should interest both the scientist and the clinician alike: polymorphisms within the factor VIII and factor IX genes, their linkage, and their ethnic variation; a general assessment of mutations within both genes and a detailed inspection of the molecular pathology of certain mutations to illustrate the ...
openaire   +4 more sources

Alternative payment models for durable and potentially curative therapies : The case of gene therapy for haemophilia A

, 2022
Introduction: The emergence of durable and potentially curative cell and gene therapies (also known as advanced therapy medicinal products) with high price tags is challenging conventional health care payment systems.
Goodman, Clifford,, Berntorp, Erik,, Goodman, Clifford, Wong, Olivier,, the International Haemophilia Access Strategy Council, Berntorp, Erik, Wong, Olivier, Lund University.   +7 more
core   +1 more source